HK1030613A1 - Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest - Google Patents

Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest

Info

Publication number
HK1030613A1
HK1030613A1 HK01100304A HK01100304A HK1030613A1 HK 1030613 A1 HK1030613 A1 HK 1030613A1 HK 01100304 A HK01100304 A HK 01100304A HK 01100304 A HK01100304 A HK 01100304A HK 1030613 A1 HK1030613 A1 HK 1030613A1
Authority
HK
Hong Kong
Prior art keywords
fragment
peptides
shiga toxin
chimeric polypeptide
therapeutic interest
Prior art date
Application number
HK01100304A
Other languages
English (en)
Inventor
Goud Bruno
Johannes Ludger
Original Assignee
Centre Nat Rech Scient
Inst Curie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient, Inst Curie filed Critical Centre Nat Rech Scient
Publication of HK1030613A1 publication Critical patent/HK1030613A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/25—Shigella (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4712—Cystic fibrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK01100304A 1997-07-18 2001-01-11 Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest HK1030613A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9709185A FR2766193B1 (fr) 1997-07-18 1997-07-18 Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
PCT/FR1998/001573 WO1999003881A2 (fr) 1997-07-18 1998-07-17 Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique

Publications (1)

Publication Number Publication Date
HK1030613A1 true HK1030613A1 (en) 2001-05-11

Family

ID=9509394

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01100304A HK1030613A1 (en) 1997-07-18 2001-01-11 Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest

Country Status (13)

Country Link
US (4) US6613882B1 (zh)
EP (1) EP1017715B1 (zh)
JP (2) JP4541538B2 (zh)
CN (1) CN1272882A (zh)
AT (1) ATE397062T1 (zh)
AU (1) AU750367B2 (zh)
CA (1) CA2296711C (zh)
DE (1) DE69839566D1 (zh)
DK (1) DK1017715T3 (zh)
ES (1) ES2307323T3 (zh)
FR (1) FR2766193B1 (zh)
HK (1) HK1030613A1 (zh)
WO (1) WO1999003881A2 (zh)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1078007B1 (en) * 1998-05-15 2005-11-23 Institut Curie Verotoxin b subunit for immunization
EP1057895A1 (de) * 1999-06-04 2000-12-06 Lohmann Animal Health GmbH & Co. KG Fusionsprotein das das Fragment B des Shigatoxins enthält, dieses enthaltende (Impf-)Stoffzusammensetzung und Verfahren zu dessen Herstellung
US20040071739A1 (en) * 1999-11-15 2004-04-15 Select Therapeutics, Inc. Methods of preparing an anti-tumor vaccine
EP1229045A1 (en) * 2001-02-01 2002-08-07 Institut Curie Universal carrier for targeting molecules to Gb3 receptor expressing cells
DE60203491D1 (de) 2002-08-02 2005-05-04 Inst Curie Paris Shiga-Toxin-Untereinheit B als Vektor zur Diagnose von Tumoren und zur Arzneimittelverabreichung an GB3-exprimierenden Tumoren
GB0524409D0 (en) * 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines
WO2008118013A2 (en) * 2007-03-23 2008-10-02 To-Bbb Holding B.V. Targeted intracellular delivery of antiviral agents
US20090214438A1 (en) * 2007-12-18 2009-08-27 Institut Curie Methods and compositions for the preparation and use of toxin conjugates
EP2072060A1 (en) 2007-12-18 2009-06-24 Institut Curie Methods and compositions for the preparation and use of toxin conjugates.
US20130107956A1 (en) 2010-07-06 2013-05-02 Koninklijke Philips Electronics N.V. Generation of high dynamic range images from low dynamic range images
EP2548571A1 (en) 2011-07-22 2013-01-23 Institut Curie Compositions having means for targeting at least one antigen to dendritic cells
EP2740491A1 (en) 2012-12-05 2014-06-11 Institut Curie Conjugates of the B-subunit of shiga toxin for use as contrasting agents for imaging and therapy
EP2740493A1 (en) 2012-12-05 2014-06-11 Institut Curie Conjugates of the B-subunit of Shiga toxin for anticancer therapies
CA2937407A1 (en) 2014-01-27 2015-07-30 Molecular Templates, Inc. De-immunized shiga toxin a subunit effector polypeptides for applications in mammals
EP3058956A1 (en) 2015-02-23 2016-08-24 Institut Curie Combined vaccination/radioterapy for cancer treatment
CN104744594B (zh) * 2015-04-21 2018-09-18 中国人民解放军第三军医大学 乙肝病毒多表位与志贺毒素的融合蛋白及其制备方法和应用
WO2016196344A1 (en) 2015-05-30 2016-12-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
AU2016297920A1 (en) * 2015-07-26 2018-01-18 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin A subunit effectors and CD8+ T-cell epitopes
WO2018106895A1 (en) 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
IL267990B2 (en) * 2017-01-25 2024-04-01 Molecular Templates Inc Cell-targeted molecules containing Shiga toxin A subunit activators and nonimmune CD8 T-cell epitopes
CA3097178A1 (en) 2018-04-17 2019-10-24 Molecular Templates, Inc. Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds
CN116236584B (zh) * 2023-02-20 2024-03-22 四川大学 一种用于高效递送siRNA的多糖-多肽偶联物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2547731A1 (fr) 1983-06-27 1984-12-28 Centre Nat Rech Scient Immunotoxine antitumorale, preparations pharmaceutiques la contenant et son utilisation in vitro
US5198344A (en) * 1986-07-15 1993-03-30 Massachusetts Institute Of Technology DNA sequence that encodes the multidrug resistance gene
US5338839A (en) * 1988-04-12 1994-08-16 Massachusetts Institute Of Technology DNA encoding nestin protein
JPH05502880A (ja) * 1989-12-22 1993-05-20 セラジェン・インコーポレーテッド トランスロケーション領域および細胞結合領域を有するハイブリッド分子
KR910014970A (ko) 1990-01-08 1991-08-31 미다 가쓰시게 가스 차단기
US6197299B1 (en) * 1990-07-20 2001-03-06 Pharmacia & Upjohn Ab Antibody conjugates
CA2077277A1 (en) 1991-09-09 1993-03-10 John J. Donnelly Cellular immunity vaccines from bacterial toxin-antigen conjugates
DE4219696A1 (de) * 1992-02-17 1993-08-19 Biotechnolog Forschung Gmbh Hybrid-dna, plasmide, oligohybridpeptid und impfstoff
AU3628193A (en) * 1992-02-18 1993-09-13 Gesellschaft Fur Biotechnologische Forschung Mbh Dysentery vaccine stimulating an immune response against shigatoxin, plasmids and host strains for it
US5350890A (en) * 1992-10-01 1994-09-27 Gould Instrument Systems, Inc. Contact switch device
CA2156191A1 (en) * 1993-02-22 1994-09-01 Stephen B. Calderwood Heterologous antigens in live cell vaccine strains
US7229755B1 (en) 1993-11-17 2007-06-12 Dana Farber Cancer Institute, Inc. Method for detection of alterations in the DNA mismatch repair pathway
US5763165A (en) * 1994-03-10 1998-06-09 Ludwig Institute For Cancer Research Method for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3
CN1173204A (zh) 1994-11-17 1998-02-11 马克西姆药物公司 刺激粘膜免疫的免疫原
EP0739984A1 (en) 1995-04-26 1996-10-30 San Tumorforschungs-Gmbh Bivalent polypeptides containing at least two domains
WO1997013410A1 (en) * 1995-10-13 1997-04-17 Boston Medical Center Corporation Hybrid molecules containing amidated polypeptide binding ligands
WO1998011229A2 (en) 1996-09-10 1998-03-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Histidine-tagged shiga toxins, toxoids, and protein fusions with such toxins and toxoids, methods for the purification and preparation thereof
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6482586B1 (en) * 1996-11-22 2002-11-19 Hospital For Sick Children Research And Development Limited Partnership Hybrid compositions for intracellular targeting
EP1078007B1 (en) 1998-05-15 2005-11-23 Institut Curie Verotoxin b subunit for immunization

Also Published As

Publication number Publication date
EP1017715B1 (fr) 2008-05-28
AU8812498A (en) 1999-02-10
JP4541538B2 (ja) 2010-09-08
CA2296711A1 (fr) 1999-01-28
CN1272882A (zh) 2000-11-08
ATE397062T1 (de) 2008-06-15
FR2766193B1 (fr) 2001-09-14
FR2766193A1 (fr) 1999-01-22
CA2296711C (fr) 2012-07-03
WO1999003881A2 (fr) 1999-01-28
WO1999003881A3 (fr) 2000-06-29
DE69839566D1 (de) 2008-07-10
ES2307323T3 (es) 2008-11-16
US20170015719A1 (en) 2017-01-19
US7488809B2 (en) 2009-02-10
US20100322913A1 (en) 2010-12-23
DK1017715T3 (da) 2008-10-06
US20040047883A1 (en) 2004-03-11
US8524652B2 (en) 2013-09-03
EP1017715A2 (fr) 2000-07-12
AU750367B2 (en) 2002-07-18
JP2010180216A (ja) 2010-08-19
US6613882B1 (en) 2003-09-02
JP2001510030A (ja) 2001-07-31

Similar Documents

Publication Publication Date Title
HK1030613A1 (en) Chimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest
MX9606492A (es) Secuencias peptidicas, guias, sinteticas.
NZ335485A (en) Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
WO1996017072A3 (en) Recombinant alphavirus vectors
DE69841038D1 (zh)
AU7261994A (en) Hydrazino-type radionuclide chelators having an n3s configuration
MX9602649A (es) Peptidos sinteticos antimicrobianos.
IL132496A0 (en) Mammalian cytokine-like factor 7
ATE394484T1 (de) Smad 6 und dessen anwendungen
HU9502920D0 (en) New bacillus thuringiensis strains and their insecticidal proteins
EP0644769A4 (en) BIOLOGICALLY ACTIVE PEPTIDES WITH N-TERMINAL SUBSTITUTIONS.
MXPA00003885A (es) Quimiocinas con modificiaciones de la terminacion amino.
WO1998057983A3 (en) Mammalian neuro-growth factor like protein
HK1001404A1 (en) Isolated, tyrosinase derived peptides and uses thereof.
EP0669396A4 (en) Novel polypeptides and DNA coding for them.
DE69938130D1 (de) Neue peptide
BR9709293A (pt) Genes de bacillus thuringiensis codificando toxinas ativas em nematóide
MX9700298A (es) Adenovirus que comprende un gen que codifica para una no sintasa.
WO1999031229A3 (en) Peptides and nucleic acids derived from eisenia foetida and the use thereof
IL89307A0 (en) Bacillus thuringiensis var.israelensis cryd toxin gene,protein and related insecticide compositions
EP0501650A3 (en) Bacillus thuringiensis genes encoding novel coleopteranactive protein toxins
AU1879097A (en) Fragments of cr1 and their use
ZA973029B (en) Expression of recombinant peptides.
ATE75255T1 (de) Peptid und dafuer kodierendes gen.
ZA965735B (en) Recombinant peptide.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150717